Literature DB >> 2903626

Microfilaraemia, filarial antibody, antigen and immune complex levels in human filariasis before, during and after DEC therapy. A two-year follow-up.

P Ramaprasad1, G B Prasad, B C Harinath.   

Abstract

A study on the effect of DEC therapy on microfilaraemia and the immune status in 27 patients with W. bancrofti infection was carried out for two years. Persistence of microfilaraemia was observed in 4 out of 27 cases after one course of DEC therapy and were treated again for one week. On further follow-up, none was microfilaraemic upto Day 60. The mean filarial antibody titres of IgM and IgG showed a gradual decrease as assessed by enzyme linked immunosorbent assay (ELISA). The mean titres of circulating microfilarial excretory-secretory (ES) antigens and immune complexes (ICs) showed an initial increase during therapy, followed by a gradual fall upto Day 60. Filarial antigen was detected in urine of all the carriers during therapy. Excretion pattern of antigen in urine showed correlation with DEC dose. Reappearance of microfilariae (mf) in circulation in 12 patients after a year showed that DEC had temporary attenuating effect on adult worms or no effect on developing larvae, suggesting further treatment and follow-up of patients. Parasitological and immunoscreening at the end of 2 years showed that the presence of mf ES antigen in blood correlated with the appearance of microfilariae in blood.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2903626

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  6 in total

1.  Heightened measures of immune complex and complement function and immune complex-mediated granulocyte activation in human lymphatic filariasis.

Authors:  Prakash Senbagavalli; Rajamanickam Anuradha; Vadakkuppattu D Ramanathan; Vasanthapuram Kumaraswami; Thomas B Nutman; Subash Babu
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

2.  Immunomonitoring followed by optimal dec therapy for successful management of clinical filariasis in an endemic area.

Authors:  B C Harinath; M V Reddy; R Alli; V K Mehta; P Chaturvedi; K R Patond; S P Kalantri; R K Gupta
Journal:  Indian J Clin Biochem       Date:  1999-07

3.  Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis.

Authors:  Britt J Andersen; Jessica Kumar; Kurt Curtis; Nelly Sanuku; Samson Satofan; Christopher L King; Peter U Fischer; Gary J Weil
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

4.  Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis.

Authors:  Britt J Andersen; Bruce A Rosa; Jonah Kupritz; Aboulaye Meite; Traye Serge; Marla I Hertz; Kurt Curtis; Christopher L King; Makedonka Mitreva; Peter U Fischer; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2019-09-26

Review 5.  Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.

Authors:  Philip J Budge; Carly Herbert; Britt J Andersen; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2018-05-16

Review 6.  An update on non-invasive urine diagnostics for human-infecting parasitic helminths: what more could be done and how?

Authors:  John Archer; James E LaCourse; Bonnie L Webster; J Russell Stothard
Journal:  Parasitology       Date:  2019-12-13       Impact factor: 3.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.